Kevin Isett, President and CEO of Avitide said, We have made tremendous progress in affinity ligand
and chromatography development over the past decade. Avitides culture of rapid and continuous technology innovation is what differentiates us from other companies and it is where we feel a strong kinship with Repligen. Repligen is the ideal
partner to drive the expanded adoption of existing products and introduction of new products to the market through the combination of their established global operational and commercial capabilities and Avitides unique and differentiated
affinity chromatography discovery platform.
Approvals and Financing
The transaction is expected to be completed during the third quarter of 2021, subject to the satisfaction of customary closing conditions. To fund the
transaction, Repligen intends to use its cash on hand, which totaled approximately $734 million at June 30, 2021. Perella Weinberg Partners LP is acting as financial advisor and Goodwin Procter LLP is serving as legal counsel to Repligen. EC
M&A is acting as the financial advisor and Morgan, Lewis & Bockius LLP is serving as the legal counsel to Avitide for the transaction.
About Repligen Corporation
Repligen Corporation is a
global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the
customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and
manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands
and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.
This press release
contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied
statements or guidance regarding the expected results of the proposed acquisition of Avitide, Inc. on Repligens future financial performance, including the accretive nature and the timing of the accretive nature of the acquisition, expected
synergies following the acquisition of Avitide, customer adoption of Avitides products, the expected expansion of Repligens product lines, the timing of the closing of the acquisition and other statements identified by words like
believe, expect, anticipate, may, will, should, seek, or could and similar expressions, constitute